Dravet (pronounced “drah-VAY”) syndrome is a rare, hard-to-treat form of epilepsy.1-4
For patients with Dravet, brain scans and tests, like an initial electroencephalogram (EEG), may appear normal.6 For that reason, genetic testing is highly recommended and may support a diagnosis.
Though not fully conclusive, research shows that over 90% of patients with Dravet syndrome have a mutation in the SCN1A gene.4,7
Getting your loved one’s seizures under control as soon as possible is an essential treatment goal. Children who experience frequent and prolonged seizures may be at risk for several medical and developmental issues.2,9
These may include:
Slow developmental progression
Delayed language development
Poor appetite and eating habits
Poor coordination
Decreased muscle tone
Inattention or hyperactive behavior
Sleep difficulties
Crouched gait
It is scary to talk about, but children with Dravet syndrome are also at risk for sudden unexpected death in epilepsy (SUDEP). Those who experience tonic-clonic seizures are at higher risk for SUDEP, and that risk increases further with seizure frequency.10,11
The good news is that as children get older:2,6,12
Each child’s development is affected differently by Dravet, and the Dravet Syndrome Foundation offers resources to support caregivers like you throughout your loved one’s life.
Use this guide to help you initiate a conversation with your loved one’s doctors to determine if DIACOMIT is the right fit for their treatment plan.
1. Wheless JW, Fulton SP, Mudigoudar BD. Dravet syndrome: a review of current management. Pediatr Neurol. 2020;107:28-40. 2. Villas N, Meskis MA, Goodliffe S. Dravet syndrome: characteristics, comorbidities, and caregiver concerns. Epilepsy Behav. 2017;74:81-86. 3. Shmuely S, Sisodiya SM, Gunning WB, Sander JW, Thijs RD. Mortality in Dravet syndrome: a review. Epilepsy Behav. 2016;64(pt A):69-74. 4. Dravet C. The core Dravet syndrome phenotype. Epilepsia. 2011;52(suppl 2):3-9. 5. Wu YW, Sullivan J, McDaniel SS, et al. Incidence of Dravet syndrome in a US population. Pediatrics. 2015;136(5):e1310-e1315. 6. Wirrell EC, Laux L, Donner E, et al. Optimizing the diagnosis and management of Dravet syndrome: recommendations from a North American consensus panel. Pediatr Neurol. 2017;68:18-24. 7. Scheffer IE, Zuberi S, Mefford HC, et al. Development and epileptic encephalopathies. Nat Rev Dis Primers. 2024(10);10(1):61. 8. Surovy M, Soltysova A, Kolnikova M, et al. Novel SCN1A variants in Dravet syndrome and evaluating a wide approach of patient selection. Gen Physiol Biophys. 2016;35:333-342. 9. Dravet Syndrome Foundation. What is Dravet syndrome? http://www.dravetfoundation.org/what-is-dravet-syndrome. Accessed November 16, 2020. 10. Wirrell EC, Hood V, Knupp KG, Meskis MA, Nabbout R, Scheffer IE, Wilmshurt J, Sullivan J. International consensus on diagnosis and management of Dravet syndrome. Epilepsia. 2022;63(7):1761-1777. 11. Sveinsson O, Andersson T, Mattsson P, Carlsson S, Tomson T. Clinical risk factors in SUDEP: A nationwide population-based case-control study. Neurology. 2020;94(4):e419-e429. 12. Dravet Syndrome Foundation. Comorbidities in Dravet syndrome. https://dravetfoundation.org/what-is-dravet-syndrome/comorbidities/. Accessed August 4, 2022.